Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
7,015 people get GSK articles and Market Currents by email alert.
Get email alerts on GSK »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
-
-
-
-
-
PR Newswire (May 10, 2013)
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
GlaxoSmithKline Positioning For Clinical Trial Data AdvantageAlan Kotok • Mon, Nov 26, 2012 -
-
-
-
-
-
-
-
-
-
-
Glaxo And Human Genome Have Apparently Seen ReasonStephen Simpson • Mon, Jul 16, 2012
-
Glaxosmithkline plc Q4 2009 Earnings Call TranscriptThu, Feb 4, 2010
-
Human Genome Sciences Inc. Q1 2009 Earnings Call TranscriptWed, Apr 29, 2009 • 1 Comment
-
Human Genome Sciences Inc Q4 2008 Earnings Call TranscriptThu, Feb 26, 2009
-
Human Genome Sciences Inc. Q3 2008 Earnings Call TranscriptThu, Nov 6, 2008
-
Human Genome Sciences Inc. Q2 2008 Earnings Call TranscriptWed, Jul 30, 2008
-
Human Genome Sciences Inc. Q1 2008 Earnings Call TranscriptMon, May 5, 2008
-
at MarketWatch.com (Mon, 12:07PM)
-
at MarketWatch.com (Mon, 12:04PM)
-
PR Newswire (May 10, 2013)
-
at CNBC.com (Apr 24, 2013)
-
at CNBC.com (Apr 23, 2013)
-
at CNBC.com (Apr 23, 2013)
-
at CNBC.com (Apr 19, 2013)
-
at MarketWatch.com (Apr 18, 2013)
-
at MarketWatch.com (Apr 18, 2013)
-
PR Newswire (Apr 17, 2013)
-
PR Newswire (Apr 17, 2013)
-
at MarketWatch.com (Apr 16, 2013)
-
at MarketWatch.com (Apr 16, 2013)
-
at CNBC.com (Apr 15, 2013)
-
at CNBC.com (Apr 11, 2013)
-
at CNBC.com (Apr 10, 2013)
GSK vs. ETF Alternatives
Company Description
Human Genome Sciences, Inc. (“HGS” or the “Company”) is a commercially focused biopharmaceutical company advancing toward the market with three products in late-stage development: BENLYSTAtm for systemic lupus erythematosus (“SLE”), ZALBINtm for chronic hepatitis C, and raxibacumab for... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Monday, March 4, 9:50 AM Shares in GSK (GSK -0.6%), Pfizer (PFE +0.3%) and Abbott (ABT +0.2%) show little reaction to news that lamivudine and zidovudine, which they sell in a JV, helped cure a 2/12 year old infant of HIV. Other firms that develop HIV treatments, including Merck (MRK +0.4%), J&J (JNJ +0.35%) and Gilead (GILD +0.3%), also don't seem too impressed. Comment! [Healthcare]
- Monday, March 4, 5:42 AM A 2 1/2 year-old infant appears to have been cured of HIV following aggressive treatment soon after birth with the drugs lamivudine and zidovudine, which are sold by a joint venture between GlaxoSmithKline (GSK), Pfizer (PFE), ViiV Healthcare and Abbott Laboratories' (ABT) Kaletra. The news could revolutionize the way babies with HIV are treated. "It's proof of principle that we can cure HIV infection if we can replicate this case," says Johns Hopkins' Deborah Persaud, the lead author of a report on the case. 5 Comments [Healthcare, Top Stories]
- Friday, March 1, 12:39 PM Hospira (HSP -0.1%) slips into the red on reports that Glaxo SmithKline (GSK +0.2%) is suing the company over the quality of its flu vaccine supply. Comment! [Healthcare]
- Wednesday, February 27, 1:58 PM Shares of Sarepta Therapeutics (SRPT +4.1%) pop after Glaxo SmithKline (GSK +0.1%) says that Duchenne muscular dystrophy patients treated with its experimental drug drisapersen have been hospitalized due to kidney toxicity and low platelet counts. SRPT is meeting with FDA officials this month to discuss the possibility of an accelerated approval filing for its DMD drug eteplirsen based on a completed phase II study. Eteplirsen's adverse event reports have been relatively unblemished to date. 1 Comment [Healthcare, On the Move]
- Tuesday, February 19, 12:00 PM Isis Pharmaceuticals (ISIS +0.6%) says it's triggered a $7.5M milestone payment from GlaxoSmithKline (GSK) related to the initiation of a Phase 2/3 clinical study for ISIS-TTR, an antisense drug for treating transthyretin amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues. Comment! [Healthcare]
- Tuesday, February 19, 11:11 AM GlaxoSmithKline (GSK +0.5%) and Theravance (THRX -1.7%) say their New Drug Application for UMEC/VI, a treatment for patients with chronic obstructive pulmonary disease, has been accepted by the FDA, giving it the go-ahead for a substantive review. The PDUFA goal date has also been set for December 18, 2013. Comment!
- Wednesday, February 6, 8:50 AM More on GSK (GSK +0.2%) Q4: CEO Andrew Witty says company is focused on organic growth and has small appetite for acquisitions; GSK expects Phase III data on 14 assets in 2013 & 2014. Witty expects some job losses in Europe due to pressure on prices, and while he declines to provide too many details of impact on headcount of restructuring, he says the R&D and manufacturing overhaul will focus on new processes rather than staff cuts. (PR) Comment! [Earnings, Healthcare]
- Wednesday, February 6, 8:43 AM More on GSK (GSK) Q4: To expand revamp, including restructuring European operations, drug manufacturing and research in an attempt to save at least £1B a year by 2016, although will take charges of £1.5B. Places Lucozade and Ribena drinks brands under strategic review. Expects core EPS growth of 3-4% CER in 2013, sales growth of 1% CER. Targeting share buybacks of £1-2B this year. (PR) Comment! [Healthcare, Earnings]
- Wednesday, February 6, 8:36 AM GlaxoSmithKline (GSK): Q4 core EPS of 32.6 pence beats by 1.3 pence; Revenues of £6.80B (-3% Y/Y) misses by £80M. Net profit -35% to £839M. Shares +0.2%. (PR) Comment! [Healthcare, Earnings]
- Tuesday, January 22, 3:25 AM GlaxoSmithKline's (GSK) Pandemrix H1N1 swine flu vaccine, which was given to over 30M people in 47 countries during the 2009-2010 H1N1 swine flu pandemic, has been linked with hundreds of cases of the incurable sleep disorder narcolepsy in Europe. GSK says there isn't yet enough data to demonstrate a causal link, although narcolepsy expert Emmanuel Mignot says the information is pointing in one direction. 2 Comments [Healthcare]
- Wednesday, January 9, 12:12 PM Theravance (THRX +3.2%) and GlaxoSmithKline (GSK +0.1%) have submitted a regulatory application to the E.U. for Anoro, an investigational combination medicine for patients with chronic obstructive pulmonary disease. The companies submitted a regulatory application in the U.S. for the drug last December. Comment! [Healthcare, On the Move, Global & FX]
- Wednesday, December 19, 2012, 4:40 PM GlaxoSmithKline (GSK) reaches a $150M preliminary settlement with U.S. drug wholesalers claiming the company improperly delayed the market entry of competitive generic alternatives to its nasal spray Flonase. The settlement was reached with AmerisourceBergen (ABC), Cardinal Health (CAH), and McKesson (MCK), among others, who maintained that GSK had abused the citizen's petition process to monopolize the market and overcharge for the spray by restricting access to less expensive generic versions. 1 Comment [Healthcare]
- Wednesday, December 19, 2012, 4:34 PM Amicus Therapeutics (FOLD) and GlaxoSmithKline (GSK) announce results from the Phase III study of its investigational oral migalastat HCl monotherapy in patients with Fabry disease, noting the pre-designated primary endpoint was not achieved. FOLD -50%, GSK -0.7% AH. 4 Comments [Healthcare, On the Move]
- Tuesday, December 18, 2012, 6:15 PM The top 10 dividend-yielding stocks from the "ultimate stock pickers" at Morningstar: GSK, COP, INTC, LLY, NVS, MRK, PM, PFE, SYY, JNJ. 14 Comments [Quick Ideas]
- Tuesday, December 18, 2012, 11:31 AM Theravance (THRX +2.4%) and GlaxoSmithKline (GSK +0.6%) have submitted a New Drug Application for the investigational drug UMEC/VI (LAMA/LABA), named Anoro Ellipta, which is a potential treatment for patients with chronic obstructive pulmonary disease. The companies also intend to file regulatory applications in the European Union as well as other countries in the coming year. Comment! [Healthcare, On the Move]
- Monday, December 17, 2012, 8:04 PM GlaxoSmithKline's (GSK) Revolade received draft guidance support from the National Institute for Health and Clinical Excellence - the financial watchdog for the U.K health system - which overturns a 2010 ruling that said the drug was too costly. The drug is a treatment for a rare disorder called chronic immune thrombocytopenic purpura, and occurs in patients who have had their spleens removed. GSK received the institute's stamp of approval after agreeing to sell it to the state-run medical system at a discount. Comment! [Healthcare]
-
Dividend Sheet
$BX $GSK and $TOT are the best yielding and most bought dividend stocks from investment gurus + http://stks.co/bKV1 + I like $INTC and $JNJ - View all 1 replies
-
-
- View all 0 replies
-
- View all 0 replies
-
- View all 2 replies
-
-
-
- View all 0 replies
-
- View all 0 replies
-
Michael Bryant
However, once European stocks correct, it is time to buy. But buy the large cap names like Glaxo SmithKline (GSK) & Heineken (HINKY.PK). - View all 0 replies
-
- View all 0 replies
-
Shane Blackmon
$SGYP FV-100 looks interesting, 1 pill per day, rather than 12 pills with Valtrex. Valtrex had 339M pounds of sales in 2011 for $GSK. - View all 2 replies
-
-
Shane Blackmon: ha, i dont have the symbol for British pounds on my computer... or else i just don't know how to do it.
-
- View all 0 replies
LATEST REPLIES
-
Scott Matusow
$ATRS moving back up nicely after epic fail bear attack on phony H&S tech Analysis. $GSK sorry missed that one! - View all 2 replies
-
-
-
- View all 1 replies
-
-
- View all 2 replies
-
-
-
Michael Bryant
Human Genome Sciences (GSK) may be a good gamble, especially with earnings coming up. - View all 1 replies
-
TruffelPig: I am waiting for the Exelexis results - they have Phase III data coming this quarter (getting nervous actually soon....)
-
- View all 1 replies
-
-
Michael Bryant
Human Genome Sciences (GSK) rose on buyout rumor. Or was this a jump because Seeking Alpha posted 3 or 4 articles on it today? - View all 3 replies
-
-
-
- View all 4 replies
-
Irishmedic: Ask Chines, but I would get rid of it in the morning, but he is king of timing -
-
- View all 6 replies
-
Mr. Massive: I was jk- he prob bought 10/22 calls otm. Process takes a while. To all. Think MA super cycle is near. Yhoo hgsi nov in money calls
-
-
campusglass
Ended up stuck with the Oct22 15$ call on GSK, bought this morning with unsettled funds like an idiot. Wanted to sell at 2 but gambling now - View all 6 replies
-
campusglass: I'm just banking on rumor/buyout/market mayhem. If nothing happens i lose lol. unlike ppl on here, I have no problem aknowledging that.
-
-
- View all 9 replies
-
campusglass: True. Thanks guys. Im taking profit don't think im jumping back in. I appreciate the advice though
-
Mr. Massive: he said it - often times with options you look at where you want the price to go and play that as opposed to playing thsoe who thinkg that
-
- View all 8 replies
-
campusglass: Mine Expire Friday, seeing it ifts worth holding the 15$ Calls I'm up on them, but i'd like to see them get in the money.
-
Michael Stuart: @CG-RETIRED: Sell now and roll over profits into longer dated ones if you still want to play? I'm in JAN 2012 ones, holding until expiration or TO
-
- View all 3 replies
-
-
Michael Stuart: Keno, lottery, maybe scratchers? Either way, I've pissed a C-note away in far more stupid ways in the market ;)
-
- View all 8 replies
-
-
-
- View all 2 replies
-
-
mbill: I believe the rumored takeover bid is just a rumor and not likely, but the price looks reasonable.
-
Michael Stuart
Bought 2 GSK $14 JAN calls @$1.80. Not expecting rumors to pan out, but feel it's a "lottery ticket" situation. - View all 2 replies
-
-
Michael Stuart: And now green on the calls, despite commissions and a massive bid/ask spread ;)